Targeting heat shock proteins in metastatic castration-resistant prostate cancer

被引:0
|
作者
Arun A. Azad
Amina Zoubeidi
Martin E. Gleave
Kim N. Chi
机构
[1] British Columbia Cancer Agency,Department of Medical Oncology
[2] The Vancouver Prostate Centre,undefined
来源
Nature Reviews Urology | 2015年 / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Heat shock proteins (HSPs) are molecular chaperones that regulate protein homeostasis, signal transduction and transcriptional networks, and are key drivers of adaptive stress-response pathways in many malignanciesHSPs are highly expressed in many cancers, and subversion of their chaperone functions enables survival of malignant cells subjected to proteotoxic stressHSPs are important in androgen receptor function (including ligand binding and nuclear trafficking), and many HSP client proteins modulate key signalling and transductional networks in castration-resistant prostate cancer (CRPC) cellsExtensive preclinical data have demonstrated the utility of targeting HSPs, including HSP90, HSP70, HSP27 and clusterin, in prostate cancerClinical development of HSP blockade as a therapeutic strategy in CRPC has been challenging, but antisense oligonucleotides targeting HSP27 and clusterin have proceeded to late-stage clinical trialsIntegrating HSP blockade into the treatment paradigm for CRPC will require the development of potent, selective inhibitors of HSPs, and identification of rational combination strategies
引用
收藏
页码:26 / 36
页数:10
相关论文
共 50 条
  • [31] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [32] Drug resistance in metastatic castration-resistant prostate cancer
    Seruga, Bostjan
    Ocana, Alberto
    Tannock, Ian F.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (01) : 12 - 23
  • [33] Emerging therapies targeting castration-resistant prostate cancer
    Gkialas, Ioarmis K.
    Fragkoulis, Charalampos
    JOURNAL OF BUON, 2015, 20 (06): : 1389 - 1396
  • [34] Comment on: Rucaparib in castration-resistant, metastatic prostate cancer
    Brandt, Maximilian
    AKTUELLE UROLOGIE, 2024, 55 (02) : 98 - 98
  • [35] Abiraterone Acetate In Metastatic Castration-Resistant Prostate Cancer
    Yang, Lily P. H.
    DRUGS, 2011, 71 (15) : 2067 - 2077
  • [36] Olaparib for Metastatic Castration-Resistant Prostate Cancer REPLY
    de Bono, Johann
    Kang, Jinyu
    Hussain, Maha
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 891 - 891
  • [37] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Abiraterone AcetateIn Metastatic Castration-Resistant Prostate Cancer
    Lily P. H. Yang
    Drugs, 2011, 71 : 2067 - 2077
  • [39] Development of enzalutamide for metastatic castration-resistant prostate cancer
    Bhattacharya, Suman
    Hirmand, Mohammad
    Phung, De
    van Os, Steve
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 13 - 27
  • [40] Metastatic castration-resistant prostate cancer: time for innovation
    Tucci, Marcello
    Scagliotti, Giorgio Vittorio
    Vignani, Francesca
    FUTURE ONCOLOGY, 2015, 11 (01) : 91 - 106